Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or future fundraising through debt or equity in the transcript. The management discusses working capital utilization and capex but does not indicate plans for new debt or equity fundraising. They highlight working capital pressures being managed through internal funds and government tenders. Asset monetization (land parcel valued around INR50 crores) is being considered, which may generate funds internally, not through equity or debt. No direct reference to raising funds via equity issuance or new borrowings was made during the Q&A or management rema

Any current/future capex/capital investment/strategic investment?

Kilitch Drugs is investing around INR 100 crores to develop a new greenfield pharmaceutical project at Khopoli, Maharashtra, India. The Khopoli plant is designed to produce: - Oral tablets with a capacity of approx. 260 million per year - Liquid injectable vials approx. 31 million per year - Liquid injectable ampoules approx. 47 million per year - Ophthalmic drops approx. 21.4 million per year - Nasal drops approx. 21.4 million per year The building construction at the Mumbai plant has started; they expect to complete the first floor slab by end of the current month. Validation and p

Future growth expectations in sales/revenue/volumes?

Expecting 20%-25% growth in sales for FY 2025 over FY 2024. Overall year-on-year growth forecasted at approximately 25%-30% for FY 2025. Export market expected to contribute around 60%-65% of revenue, domestic market around 30%-40%. Expansion of Khopoli plant (INR 100 crores investment) to start operations with validation by May 2025, producing: - Oral tablets: approx. 260 million units/year - Liquid injectable vials: approx. 31 million units/year - Liquid injectable ampoules: approx. 47 million units/year New facility designed considering client demand, especially near Mumbai for better

Future growth expectations in earnings/operating earnings/profits/EPS?

Kilitch Drugs India Limited expects a revenue growth of around 25%-30% year-on-year for FY 2025. EBITDA margins are projected to be maintained or improved in the range of 18%-22%. The company targets achieving INR 500 crores in revenue by 2027, with EBITDA margins remaining at approximately 22%-24%. The Ethiopian facility is expected to increase capacity utilization to around 60% in the current fiscal year, supporting strong margin expectations of 20%-25% EBITDA in that market. New product development, particularly for export markets such as Kenya, is expected to commence in FY 2025, a

Current/ Expected Orderbook/ Pending Orders?

Kilitch Drugs has secured a significant government tender in Ethiopia worth USD 9.13 million, which will commence execution from Q2 FY24. The company expects this government order to trigger around 60% utilization of their Ethiopian facility capacity for the whole year. The facility is expected to run more efficiently and potentially add 20%-30% more orders beyond the government tender. For 2025, the new Khopoli plant validation starts May 25, with planned capacity: 260 million oral tablets, 31 million injectable vials, 47 million injectable ampoules annually. Demand near Mumbai is driven by c

Kilitch Drugs (India) LtdQ4 FY24Pharmaceuticals & Biotechnology

Kilitch Drugs (India) Ltd Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹201.32P/E: 23.5Market Cap: ₹705 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 2

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

Expecting 20%-25% growth in sales for FY 2025 over FY 2024.
Overall year-on-year growth forecasted at approximately 25%-30% for FY 2025.
Export market expected to contribute around 60%-65% of revenue, domestic market around 30%-40%.
Expansion of Khopoli plant (INR 100 crores investment) to start operations with validation by May 2025, producing:
- Oral tablets: approx. 260 million units/year
- Liquid injectable vials: approx. 31 million units/year
- Liquid injectable ampoules: approx. 47 million units/year
New facility designed considering client demand, especially near Mumbai for better QA audits and logistics.
Ethiopian facility utilization expected to reach around 60% capacity in FY 2024 with government tenders boosting revenues.
Continued focus on product development and launching new products, especially for export markets like Kenya starting FY 2025.

Margin guidance

Category 2

Kilitch Drugs India Limited expects a revenue growth of around 25%-30% year-on-year for FY 2025.
EBITDA margins are projected to be maintained or improved in the range of 18%-22%.
The company targets achieving INR 500 crores in revenue by 2027, with EBITDA margins remaining at approximately 22%-24%.
The Ethiopian facility is expected to increase capacity utilization to around 60% in the current fiscal year, supporting strong margin expectations of 20%-25% EBITDA in that market.
New product development, particularly for export markets such as Kenya, is expected to commence in FY 2025, aiding growth and margin improvement.
The upcoming Khopoli plant, with a capacity for producing 260 million oral tablets and other dosage forms, is planned to start validation by May 2025, contributing to future growth.
Overall, the company anticipates sustained profitability growth driven by operational expansion and increased export business.

See what Kilitch Drugs (India) Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of any current or future fundraising through debt or equity in the transcript.
The management discusses working capital utilization and capex but does not indicate plans for new debt or equity fundraising.
They highlight working capital pressures being managed through internal funds and government tenders.
Asset monetization (land parcel valued around INR50 crores) is being considered, which may generate funds internally, not through equity or debt.
No direct reference to raising funds via equity issuance or new borrowings was made during the Q&A or management remarks.

Order book

Yes

Kilitch Drugs has secured a significant government tender in Ethiopia worth USD 9.13 million, which will commence execution from Q2 FY24.
The company expects this government order to trigger around 60% utilization of their Ethiopian facility capacity for the whole year.
The facility is expected to run more efficiently and potentially add 20%-30% more orders beyond the government tender.
For 2025, the new Khopoli plant validation starts May 25, with planned capacity: 260 million oral tablets, 31 million injectable vials, 47 million injectable ampoules annually.
Demand near Mumbai is driven by client requirements for closer logistics and QA audits, indicating existing and new clients will supply from Khopoli in 2025.
The company foresees a 25%-30% year-on-year growth for FY25, maintaining a 60%-65% export and 30%-40% domestic sales ratio.
Private market orders in Ethiopia are expected to increase as currency and government tender issues ease.

See what Kilitch Drugs (India) Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Kilitch Drugs is investing around INR 100 crores to develop a new greenfield pharmaceutical project at Khopoli, Maharashtra, India.
The Khopoli plant is designed to produce:
- Oral tablets with a capacity of approx. 260 million per year
- Liquid injectable vials approx. 31 million per year
- Liquid injectable ampoules approx. 47 million per year
- Ophthalmic drops approx. 21.4 million per year
- Nasal drops approx. 21.4 million per year
The building construction at the Mumbai plant has started; they expect to complete the first floor slab by end of the current month.
Validation and production commencement is planned by May 25, 2024, in phased manner (Phase 1, 2, 3).
Capex of around INR 50 crores was incurred for the Ethiopian facility till 2021, with production starting in 2021.
No major capex since then for Ethiopian facility; focus is on utilizing the existing facility and expanding markets.
Land parcel valued around INR 50 crores being considered for monetization, but no immediate plans to sell.

Track Kilitch Drugs (India) Ltd — get its next earnings analysis in your feed

How does Kilitch Drugs (India) Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisKilitch Drugs (India) Ltd

Rev 2Mar 2

See where Kilitch Drugs (India) Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Kilitch Drugs (India) Ltd rank in Pharmaceuticals & Biotechnology?

Compare Kilitch Drugs (India) Ltd against every Pharmaceuticals & Biotechnology company (Q4 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Kilitch Drugs (India) Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Accretion Pharmaceuticals Ltd (Q2 FY27)
25.85% increase) . Key results statement takeaways from Accretion Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Sigachi Industries Ltd (Q2 FY27)
Year-on-Year (YoY) Revenue Growth: 18.09% (Q2 FY27 vs Q2 FY26) . Key investor presentation takeaways from Sigachi Industries Ltd's Q2 FY27 investor presentation
Advanced Enzyme Technologies Ltd (Q2 FY27)
Q2 FY27 revenue from operations: ₹2,145 million, up 16% YoY from ₹1,845 million in Q2 FY26 (Page 13, 5). Key investor presentation takeaways from Advanced Enzym
IOL Chemicals (Q2 FY27)
Q2 FY27 revenue from operations: ₹795.0 Cr, a 40.1% year-on-year (YoY) increase from ₹567.5 Cr in Q2 FY26 (Page 7). Key investor presentation takeaways from IOL

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Kilitch Drugs (India) Ltd Q4 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Kilitch Drugs (India) Ltd rank in Pharmaceuticals & Biotechnology?

Continue your research

What Kilitch Drugs (India) Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season